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MIB-1 labelling index is an independent prognostic
marker in primary breast cancer
RLH Jansen1, PSGJ Hupperets1, JW Arends2, SR Joosten-Achjanie1, A Volovics3, HC Schouten1 and HFP Hillen1
Departments of 'Internal Medicine and 2Pathology, University Hospital Maastricht, The Netherlands; 3Department of Methodology and Statistics, University
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Summary The proliferative activity of a tumour is considered to be an important prognostic factor in primary breast cancer. We have
investigated the prognostic value of the MIB-1 labelling index in 341 patients with primary breast cancer and compared the results with the
S-phase fraction in 220 patients of the same cohort. All patients were treated in one hospital and had a median follow-up of 128 months. No
correlation between MIB-1 labelling and S-phase fraction could be demonstrated. MIB-1 had prognostic value for disease-free survival in the
whole group of patients (P < 0.001) and in the node-negative subgroup (P < 0.001). In multivariate analysis, MIB-1 was an independent
prognostic factor (P= 0.004) besides axillary lymph node status (P = 0.001). In univariate analysis high S-phase fraction was associated with
decreased overall survival (P = 0.04); however, not in multivariate analysis. Moreover, S-phase fraction had a borderline prognostic
significance for post-relapse survival in multivariate analysis (P= 0.08). Thus, in conclusion, the growth fraction of a tumour as determined by
the MIB-1 labelling index is an important prognostic factor in patients with primary breast cancer.
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In primary breast cancer the axillary lymph node status is still the
most important prognostic factor and is used for deciding on adju-
vant treatment. However, an axillary lymph node dissection itself
has no or at best a very limited influence on disease-free survival
and it causes substantial morbidity (Epstein 1995; Fentiman et al,
1996). Moreover, the prognostic value of the axillary lymph node
status is not absolute, as 30% of node-negative patients still die
within 10 years because ofrecurrent disease and 30% ofnode-posi-
tive patients survive 10 years without disease (Harris et al, 1996).
Therefore, routine axillary lymph node dissection has recently
become a matter of debate (Fentiman et al, 1996) and search for
other factors to identify patients at high risk of (early) relapse is
thus needed. Many prognostic factors have been investigated, but
so far no single factor or combination of factors can be used for
treatment decisions in an individual patient. The proliferative
activity of a tumour is, however, an important prognostic factor
known to have an inverse relationship with the survival ofpatients
with breast cancer. It can be measured by different methods, all of
which have their own advantages and disadvantages. First,
counting the number of mitoses in a haematoxylin- and eosin-
stained slide is still an inexpensive method for the assessment of
tumour cell proliferation. The mitotic index (MI) may be repro-
ducible as shown in one study (Van Diest et al, 1992), but there is
no general agreement on this. The independent prognostic value of
the MI has been shown in a few studies (Clayton et al, 1991).
Second the thymidine labelling index (TLI), reflecting the prolif-
erative activity, has been claimed to be a strong and independent
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prognostic factor (Silvestrini et al, 1994, 1995). However, like the
bromodeoxyuridine labelling index, viable tissue is needed, which
makes these methods hard to apply in a routine setting.
Third, DNA flow cytometry can be used to measure the
percentage of cells in the S-phase in the cell cycle. In 1992 the
DNA Cytometry Consensus Conference concluded that the litera-
ture supported a clear association between high S-phase fraction
and an increased risk of recurrence and mortality for both axillary
node-negative and node-positive breast cancer patients (Hedley et
al, 1993). A disadvantage of this technique, however, is that
tumour heterogeneity cannot be assessed, and 10-20% of speci-
mens are not evaluable because of a large coefficient of variation
or admixture of stromal cells.
Finally, in the evaluation of proliferative activity there are also
immunohistochemical methods using antibodies directed against
nuclear antigens expressed during the cell cycle. Mainly applied is
the Ki-67 antibody, which binds to a large, non-histone nuclear
protein that is expressed in the late G,-, S-, G1- and M-phase ofthe
cell cycle. Originally the antibody could only be used on fresh or
frozen sections. More recently monoclonal antibodies such as
MIB-1, raised against parts of Ki-67 antigen, that can be used on
formalin-fixed and routinely processed archival tissue (Gerdes et
al, 1992) have become available. Several studies have shown a
close correlation between the Ki-67 results on frozen sections and
the MIB-1 findings on paraffin sections (Gerdes et al, 1992;
Remmele et al, 1995; Veronese et al, 1996), but the prognostic
value ofboth antibodies is not necessarily the same. Many studies
have been performed using Ki-67 in breast cancer and at least nine
of these studies reported on correlations between Ki-67 and
disease-free survival (DFS) and/or overall survival (OS)
(Bouzubar et al, 1989; Weikel et al, 1991; Gaglia et al, 1993; Railo
et al, 1993; Veronese et al, 1993; Rudas et al, 1994; Gasparini et al,
1994; Keshgegian et al, 1995). Seven of these studies demon-
strated significant difference with respect to prognosis in patients
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with high and low Ki-67 labelling (Bouzubar etal, 1989; Weikel et
al, 1991; Gaglia et al, 1993; Railo et al, 1993; Veronese et al, 1993;
Gasparini et al, 1994; Brown et al, 1996). However, follow-up was
mostly short and, in addition, multivariate analyses have been
performed in only four ofthese studies (Gaglia et al, 1993; Railo et
al, 1993; Rudas et al, 1994; Brown et al, 1996). Three of these
studies showed significant correlations between high Ki-67
labelling and shorter disease-free survival (Gaglia et al, 1993;
Railo et al, 1993; Brown et al, 1996).
Fewer studies have been performed with the MIB-1 antibody. In
general, the MIB-1 index also seems to be a prognostic factor
sometimes even in multivariate analyses, but follow-up is gener-
ally rather short and/or the number ofpatients is low (Jensen et al,
1995; Domagala et al, 1996; Seshadri et al, 1996; Pietilainen et al,
1996; Veronese et al, 1996).
Not many studies have been performed comparing the different
methods of assessing the proliferative activity of a tumour.
Because immunohistochemical methods seem most suitable in a
routine setting, we investigated MIB-1 immunoreactivity in a
group of 341 patients uniformly treated in one hospital with a
median follow-up of 128 months, compared the results with the S-
phase fraction in 220 patients of the same cohort and examined
correlations with other clinicopathological factors previously
studied by our group.
PATIENTS AND METHODS
Patients
The 341 patients were treated at the University Hospital Maastricht
in the period May 1982 to August 1987. Patients were selected
according to the following criteria: (1) primary unilateral breast
cancer without distant metastases; (2) no other primary tumour; (3)
histological material available. All patients were staged at the time
of diagnosis according to the International Union Against Cancer
TNM classification. The median age was 57 years (range 25-87
years). A total of 220 patients (64.5.%) had undergone a modified
radical mastectomy, 97 patients (28.5%) a lumpectomy with axil-
lary lymph node dissection and in 24 patients (7.0%) only a biopsy
was performed, because ofeither T4 stage or advanced age, in four
patients with an axillary lymph node dissection. A total of 183
patients (53.7%) had no axillary lymph node metastases, 138
patients (40.4%) had metastases in one or more axillary lymph
nodes, whereas in 20 patients (5.9%) the axillary lymph node status
was unknown. Axillary lymph node-positive patients younger than
70 years were treated with adjuvant chemotherapy consisting of5-
fluorouracil, doxorubicin and cyclophosphamide. If they agreed to
participate in a clinical trial, they were randomized forconcomitant
treatment with orwithout medroxyprogesterone acetate. The results
ofthe clinical trial have been described elsewhere (Hupperets et al,
1993; 1995). Axillary lymph node-negative patients received no
adjuvant systemic therapy. The median follow-up of all patients
was 128 months (range 61-170 months).
Methods
Steroid receptors
The oestrogen receptor (ER) and progesterone receptor (PR)
assays were all performed on histologically proven breast cancer
tissues using the dextran-coated charcoal method with multiple-
point Scatchard plot analysis.
For all the assays the minimum cytosol protein concentration
was 2 mg ml-' cytosol. PR status was determined only in patients
entered from August 1983.
Tumours with ER or PR > 10 fmol mg-' protein were con-
sidered ER or PR positive.
Flow cytometric evaluation ofploidy status and S-phase
fraction
Flow cytometric determination of DNA levels was performed on
nuclei isolated from paraffin-embedded tissue (Schutte et al, 1985;
Hedley, 1989). Sections (50 jm) were cut from formalin-fixed,
paraffin-embedded tissue blocks of the primary tumours. An adja-
cent 5-jm section was cut for histological control. DNA content
was measured by the method of Vindel0v et al (1984). Tumours
with a single G, peak were considered to be diploid, whereas
evidence of an additional peak indicated aneuploidy. DNA index
(DI) was calculated as the ratio of aneuploid to diploid GI/o peak
level. Histograms with coefficients of variation less than 8% were
considered ofgood quality. The S-phase fraction (SPF) was calcu-
lated by counting the number of cells between the inclination
points of the descending G, peak and the ascending G2/M peak
(Hiddemann et al, 1984). In cases of less than 30% admixture of
diploid cells, the percentage ofaneuploid S-phase cells was calcu-
lated without corrections for the presence of diploid S- and G2/M-
phase cells. In cases of more than 30% admixture of diploid cells
in overlap in diploid and hyperdiploid histograms the percentage
of S-phase cells was not calculated. After descriptive analysis the
cut-off levels for the proportion of S-phase cells were set at < 8%
and > 8% in order to define two groups, with low and high SPF
respectively.
Immunohistochemistry
Staining was performed using the mouse monoclonal antibody
MIB-1 (Dianova, Hamburg, Germany; 1: 100, 1 h incubation at
room temperature) and rabbit polyclonal antibody NCL-pS2
(Novocastra Laboratories Ltd, Sanbio, Newcastle, UK; 1:400, 1 h
incubation at room temperature). All antibodies were diluted in
0.5% BSA (bovine serum albumin, Sigma) containing PBS (phos-
phate-buffered saline, pH 7.4). To reach optimal staining results
for MIB-1 antigen unmasking was necessary by microwave
antigen retrieval with citric buffer (Shi et al, 1991) (0.01 M, pH
6.0). All staining procedures were performed using a standard
method. In short, 3-jim sections were cut from routinely formalin-
fixed and paraffin-embedded archival tumour samples. The MIB-
1 sections were incubated overnight in a 60°C oven on APS
(3-aminopropyltrietoxysilane, Sigma)-coated glass slides, to
obtain optimal fixation. Deparaffinization in xylene and washes in
100% ethanol were followed by removing endogenous peroxidase
in 0.3% hydrogen peroxide containing methanol (30 min, room
temperature). After washing away the excessive amount of
methanol in demineralized water, the necessary antigen
unmasking procedure was performed. Non-specific binding ofthe
antibodies was blocked with 5% BSA containing PBS. Then, the
primary antibodies were mounted on the tumour sections.
Excessive amounts of antibodies were washed away in PBS. The
avidin-biotin-peroxidase complex (Vectastain ABC Kit, Vector
Laboratories, CA, USA) method was used to obtain a threefold
amplification of the primary antigen-antibody bindings. These
bindings were highlighted with DAB (di-amino-benzidine,
Sigma). Finally, counterstaining with haematoxylin completed the
procedure.
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Table 1 Correlation between MIB-1 and other factors
MIB-1 <7% MIB-1 > 7% Number P-value
ER < 10 fmol mg-' protein 35 60 330 < 0.001
ER > 10 fmol mg-' protein 134 101
PR < 10fmol mg-' protein 55 67 264 0.01
PR > 10 fmol mg-' protein 86 56
Age < 50 years 59 52 341 0.74
Age > 50 years 118 112
Ductal carcinoma 126 127 341 0.18
Other histological types 51 37
Node-negative 111 72 321 < 0.001
Node-positive 57 81
Tumour size
T= 1 88 61 341 0.02
T > 1 89 103
Diploid 76 50 320 0.005
Aneuploid 86 108
S-phase fraction < 8% 57 43 220 0.50
S-phase fraction > 8% 63 57
pS2 negative*a 85 75 332 0.72
pS2 positivea 88 84
a By immunohistochemistry.
The percentage of breast cancer cells showing a positive
immunohistochemical reaction in a representative section of each
tumour was determined by counting the number of positively
stained cells in 1000 cancer cells for MIB-1 and 500 tumour cells
for pS2. For pS2, tumours were considered positive if at least 1%
of tumour cells showed staining comparable with previously
described classifications (Horiguchi et al, 1996).
Statistical analysis
Disease-free survival was defined as the time from the day ofdiag-
nosis until the time offirst relapse, death or last follow-up.
Overall survival was defined as the time from the day of diag-
nosis until the day ofdeath or last follow-up.
Statistical analysis was performed using the statistical packages
SAS (SAS Institute, Cary, NC, USA) and S-plus (Statistical
Sciences Europe, Oxford, UK). The association between the
expression of MIB-1 and other possible prognostic factors was
analysed by the chi-square test. Curves for disease-free survival
and overall survival were estimated by the Kaplan-Meier method.
Differences were analysed using the log-rank test. Finally, prog-
nostic variables were included in a Cox regression analysis.
RESULTS
MIB-1 labelling index
Of the 341 tumours, 14 (4.1%) showed less than 1% positive
tumour cells. The distribution ofthe percentage ofstaining tumour
cells was asymmetric (range 0-71%; mean 11.0%, median 7.0%).
The relationship between MIB-1 labelling index when
dichotomized at the median value (< 7% vs > 7%) and other clin-
ical and histological variables is shown in Table 1. High MIB-1
was associated with aneuploidy (P = 0.005), ER negativity (P <
0.001), PR negativity (P = 0.01), the presence of axillary lymph
node metastases (P < 0.001) and larger tumour size (P = 0.02).
MIB-1 staining showed no corelation with age, histology or pS2
status. Concerning histology, however, all nine tubular carcinomas
had a low MIB-1 labelling index, whereas medullary carcinomas
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Figure 1 Disease-free survival curves for the whole group of 341 patients
with low MIB-1 labelling index (< 7%) and high MIB-1 labelling index (> 7%)
(P< 0.001)
had a significantly higher MIB-1 labelling index than ductal carci-
nomas (P < 0.05). No correlation at all was shown between high
MIB-1 and high S-phase fraction (P = 0.50), whereas the Pearson
correlation coefficient was 0.15. For diploid tumours the Pearson
correlation coefficient was - 0.09 and for aneuploid tumours 0.25.
In univariate analysis it was demonstrated that high MIB-1
(> 7%) was associated significantly with shorter disease-free
survival (P < 0.001, Figure 1). Looking at subgroups, the same
was found for node-negative patients (P < 0.001; Figure 2)
whereas in node-positive patients no significant difference in
disease-free survival was demonstrated (P = 0.24, Figure 2).
Furthermore, every cut-off point of MIB-1 from 2% to 25%
showed a significant effect on disease-free survival in univariate
analysis. In multivariate analysis high MIB-l (> 7%) was, besides
the presence of axillary lymph node metastases, the only indepen-
dent prognostic factor for shorter disease-free survival (P = 0.004;
Table 2). The same was true when MIB-1 was analysed as a
continuous variable (P = 0.005, data not shown). High MIB-1
(> 7%) showed a borderline significant association with overall
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Figure 2 Disease-free survival curves for the group of 183 node-negative
patients and the group of 138 node-positive patients with low MIB-1 labelling
index (< 7%) and high MIB-1 labelling index (> 7%) (P < 0.001 and P = 0.24
respectively)
Table 2 Multivariate analysis for disease-free survival
RHRa P-value
MIB-1 (> 7 vs < 7%) 1.668 0.004
T-stage (T2 vs T1) 1.311 0.154
T-stage (T3 vs T1) 1.760 0.054
Node status (positive vs negative) 1.839 0.001
Ploidy status (aneuploid vs diploid) 1.412 0.122
SPF (> 8 vs <8%) 1.281 0.287
ER (> 10 vs < 10 fmol mg-' protein) 1.430 0.089
PR (> 10 vs < 10 fmol mg-' protein) 0.876 0.500
Age (> 50 vs < 50 years) 1.007 0.971
aRelative hazard rate.
survival in the whole group ofpatients (P = 0.05, Figure 3) but not
in the node-negative and node-positive subgroups.
In multivariate analysis for overall survival only the presence of
axillary lymph node metastases, T-stage more than T, and age
above 50 years, but not MIB-1 labeling index, were independent
prognostic factors (Table 3). Furthermore, MIB-1 was not associ-
ated with post-relapse survival.
S-phase fraction
High S-phase fraction (> 8% vs < 8%) was related with a signifi-
cantly decreased overall survival in univariate analysis (P = 0.04;
Figure 4). The effect of high S-phase fraction on overall survival
was lost in multivariate analysis (Table 3). Concerning disease-
free survival the effect of high S-phase fraction was borderline
significant (P = 0.06). With respect to post-relapse survival high
S-phase fraction was also an unfavourable prognostic factor
(P = 0.03). In multivariate analysis S-phase fraction was a border-
line prognostic factor looking at post-relapse survival (P = 0.08;
Table 4).
Combined prognostic value of MIB-1 and S-phase
fraction
Looking at a possible combined prognostic value of MIB- 1 and
S-phase fraction, only with respect to disease-free survival was
MIB-1 labelling index a significant prognostic factor both for
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Figure 3 Overall survival curves for the whole group of 341 patients with
low MIB-1 labelling index (< 7%) and high MIB-1 labelling index (> 7%)
(P= 0.05)
Table 3 Multivariate analysis for overall survival
RHRa P-value
MIB-1 (> 7 vs < 7%) 1.091 0.598
T-stage (T2 vs T1) 1.262 0.205
T-stage (T3 vs T1) 2.001 0.014
Node status (positive vs negative) 1.595 0.008
Ploidy status (aneuploid vs diploid) 0.933 0.741
SPF (> 8 vs < 8%) 1.451 0.089
ER (> 10 vs < 10 fmol mg-' protein) 1.194 0.370
PR (> 10 vs < 10 fmol mg-' protein) 0.802 0.241
Age (> 50 vs < 50 years) 1.827 0.002
aRelative hazard rate.
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Figure 4 Overall survival curves for the group of 220 patients with low
S-phase fraction (< 8%) and high S-phase fraction (> 8%) (P = 0.04)
patients with tumours with low and high S-phase fraction (P <
0.01 in both cases). Concerning overall survival MIB-1 labelling
index had an additional prognostic value only in cases of a high S-
phase fraction (P = 0.03). With respect to post-relapse survival no
differences between subgroups could be demonstrated.
DISCUSSION
In this study with long follow-up, MIB- 1 expression was a signifi-
cant prognostic factor for disease-free survival both in univariate
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Table 4 Multivariate analysis for post-relapse survival
RHRa P-value
MIB-1 (> 7 vs < 7%) 0.959 0.838
T-stage (T2 vs T1) 1.328 0.261
T-stage (T3 vs T1) 2.417 0.019
Node status (positive vs negative) 1.202 0.428
Ploidy status (aneuploid vs diploid) 0.950 0.841
SPF (> 8 vs < 8%) 1.585 0.083
ER (> 10 vs < 10 fmol mg-' protein) 0.624 0.073
PR (> 10 vs . 10 fmol mg-' protein) 0.768 0.263
Age (> 50 vs < 50 years) 1.300 0.242
aRelative hazard rate.
and multivariate analysis, for both the whole group ofpatients and
the 183 node-negative patients. MIB-1 expression had borderline
significant influence on overall survival. Not many studies have as
yet investigated MIB-I as a prognostic factor. Three studies have
demonstrated a significant influence of MIB-1 on overall survival
but have not mentioned disease-free survival (Jensen et al, 1995;
Pinder et al, 1995; Domagala et al, 1996). The largest study on
MIB-1 has shown a significant influence of MIB-I on both
disease-free and overall survival in multivariate analysis (Seshadri
et al, 1996) after a follow-up of66 months. Remarkably, however,
by far the largest study on Ki-67 in 674 node-negative breast
cancer patients has found a significant influence on disease-free
but not overall survival as in our study (Brown et al, 1996).
Several other studies have also shown a significant association of
Ki-67 and disease-free survival (Bouzubar et al, 1989; Weikel et
al, 1991; Gaglia et al, 1993; Railo et al, 1993; Veronese et al, 1993;
Gasparini et al, 1994) and Ki-67 and overall survival (Veronese et
al, 1993; Gasparini et al, 1994). Only two studies have not found
such an association between Ki-67 and disease-free survival
(Rudas et al, 1994; Keshgegian et al, 1995). The results of the
latter two studies could be explained by dividing the patients into
three groups (Rudas et al, 1994) and by arelatively short follow-up
period (Keshgegian et al, 1995) respectively. However, multi-
variate analysis was not often performed. In our study we found a
significant influence of MIB-1 on disease-free survival in node-
negative, but not node-positive patients. Comparable results have
been found in two other studies (Pietilainen et al, 1996; Querzoli et
al, 1996), whereas one study has demonstrated an effect of MIB-1
on disease-free survival for both groups ofpatients (Seshadri et al,
1996). A difference in the prognostic value of MIB-1 for node-
negative and node-positive patients could be explained by more
susceptibility for adjuvant (chemo)therapy in node-positive
patients with high MIB-1 labelling index, whereas node-negative
patients were not treated by adjuvant systemic therapy.
The median percentage of MIB-1-positive cells in our patients
(7%) tended to be lower than the median value of 16-20%
reported from several other studies (Jensen et al, 1995; Domagala
et al, 1996; Veronese et al, 1996), but is comparable with the
median value oftwo other reports (Keshgegian et al, 1995; Ellis et
al, 1996). For Ki-67 as measured in frozen sections quite different
median values varying from 2% (Brown et al, 1996) to 12%
(Bouzubar et al, 1989) are also reported. The reason for the consid-
erable variability in Ki-67 and MIB-1 scores in the different
studies is not directly clear. It seems likely that these differences
can be explained at least partly because of different methodology
(different antibodies, different staining methods, different ways of
counting). Therefore, it is certainly possible that comparable
results of the MIB-1 (and Ki-67) labelling index will be found in
different laboratories, when a uniform methodology is applied. In
general, in comparative studies a good statistical correlation is
found between Ki-67 and MIB-1 (Remmele et al, 1995; Veronese
et al, 1996).
In this study a low correlation coefficient of 0.15 between
MIB-1 and SPF was found, which seems in line with the result of
another study reporting on low correlation coefficients between
Ki-67 and SPF (Brown et al, 1996) (Spearman rank correlation of
0.15). Several other studies reported higher correlation coefficients
between Ki-67 and SPF (Keshgegian et al, 1995) and between
MIB-1 and SPF (Ellis et al, 1996). In general, correlations are
based on aneuploid tumours as in our study (Ellis et al, 1996;
Dettmar et al, 1997). However, it has to be kept in mind that the
Ki-67/MIB-1 nuclear antigen is present in all parts ofthe cell cycle
whereas S-phase only relates to one specific stage in the cell cycle.
In the literature, data on the prognostic significance of SPF are
conflicting and sometimes based on a low number of patients.
When comparing MIB-1 and SPF in multivariate analysis, one
study has found SPF to be better than MIB- 1 (Dettmar et al, 1997),
contradictory to our results. This could be explained by different
methodology and patient selection. SPF is, however, not a method
that is easily applied in routine practice.
Therefore, at this moment Ki-67 as measured on frozen sections
or MIB-l as measured on paraffin sections is probably the best
method for assessing proliferation in a routine setting. This and
several other studies have demonstrated the independent prog-
nostic value ofKi-67 and MIB- 1 in breast cancer patients. As with
most other newer prognostic markers, however, at this moment it
is not possible to use them for clinical decision-making. For that
purpose it is at least necessary that a uniform methodology is
developed.
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